Literature DB >> 21459960

Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus.

Chiara Giannitti, Gian Domenico Sebastiani, Stefania Manganelli, Mauro Galeazzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21459960     DOI： 10.3899/jrheum.101157

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  3 in total

1.  Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report.

Authors:  Pasquale De Nardo; Rita Bellagamba; Angela Corpolongo; Elisa Gentilotti; Fabrizio Taglietti; Silvia Rosati; Mauro Galeazzi; Gian Domenico Sebastiani; Isabella Quinti; Emanuele Nicastri
Journal:  Clin Vaccine Immunol       Date:  2013-03-06

2.  Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.

Authors:  Ying-Qian Mo; An-Qi Liang; Jian-Da Ma; Le-Feng Chen; Dong-Hui Zheng; H Ralph Schumacher; Lie Dai
Journal:  BMC Musculoskelet Disord       Date:  2014-12-22       Impact factor: 2.362

3.  Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.

Authors:  Ying-Ming Chiu; Mei-Shu Lai; K Arnold Chan
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.